Overall, these findings suggest that activation of FPR1 signaling is one of key drivers of hyperoxia induced lung inflammation and the ensuing lung injuries, thereby highlighting a potential new therapeutic target for BPD. The gene discussed is FPR1; the disease is bronchopulmonary dysplasia.